drugset / Trial / NCT04165772

Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

NCT04165772 ↗

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to find out whether the study drug, TSR-042, followed by standard chemoradiotherapy (the chemotherapy drug capecitabine + radiation therapy) and standard surgery is an effective treatment for advanced dMMR solid tumors. The study will also look at the safety of the study drug.

Timeline

Start
2019-12-11
Primary completion
2026-11-30
Completion
2026-11-30

Outcome

Met primary endpoint

paper A total of 37 patients had a sustained clinical complete response at 12 months, a finding that met the criterion for efficacy. PMID 40293177 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Dostarlimab Monoclonal antibody 500 mg Intravenous
Background Capecitabine Small molecule 825 mg/m2 Oral
Background fluorouracil Small molecule — —

Indications